Formoterol, montelukast, and budesonide in asthmatic children: Effect on lung function and exhaled nitric oxide

Respiratory Medicine

Volumn 101, Issue 8, 2007, Pages 1809-1813

  Miraglia del Giudice, Michele ^a   Piacentini, Giorgio L ^b   Capasso, Michele ^a   Capristo, Carlo ^a   Maiello, Nunzia ^a   Boner, Attilio L ^b   Capristo, Angelo F ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Asthma; Budesonide; Exhaled nitric oxide; FEV1; Formoterol; Montelukast

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FORMOTEROL; LONG ACTING DRUG; MONTELUKAST; NITRIC OXIDE; PLACEBO;

ADD ON THERAPY; ALLERGIC ASTHMA; ARTICLE; CHILDHOOD DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SCHOOL CHILD; TREATMENT DURATION;

ACETATES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BREATH TESTS; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; NITRIC OXIDE; QUINOLINES;

EID: 34250617567     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.02.010     Document Type: Article

References (24)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO workshop report. National Institute of Health, NIH Publication No. 02-3659 May 2002.
2. Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 19 (2002) 182-191
3. Hay D.W. Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Chest 111 (1997) 35S-45S
4. Gibson P.J. Monitoring the patient with asthma: an evidence-based approach. J Allergy Clin Immunol 106 (2000) 17-26
5. Rytila P., Metso T., Heikkinen K., Saarelainen P., Helenius I.J., and Haahtela T. Airway inflammation in patients with symptoms suggesting asthma but with normal lung function. Eur Respir J 16 (2000) 824-830
6. Nelson B.V., Sears S., Woods J., et al. Expired nitric oxide as a marker for childhood asthma. J Pediatr 130 (1997) 423-427
7. Piacentini G.L., Bodini A., Costella S., et al. Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children. Eur Respir J 13 (1999) 1386-1390
8. Warke T.J., Fitch P.S., Brown V., et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax 57 (2002) 383-387
9. Lim S., Jatakanon A., John M., et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 159 (1999) 22-30
10. Smith A.D., Cowan J.O., Brassett K.P., Herbison G.P., and Taylor D.R. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 352 (2005) 2163-2173
11. American Thoracic Society Committee on Diagnostic Standards. Definitions and classification of chronic bronchitis, asthma, and pulmonary emphysema. Am Rev Respir Dis 85 (1962) 762
12. Slutsky A.S., Drazen J.M., Silkoff P.E., et al. ATS/ALA recommendations for a standardized procedure for the on-line measurement of exhaled nitric oxide in adults and children. American Thoracic Society. Am J Respir Crit Care Med 160 (1999) 2104-2117
13. American Thoracic Society. Standardization of Spirometry. Am Rev Respir Dis 136 (1987) 1285-1298
14. Fish J.E., Israel E., Murray J.J., et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 120 (2001) 423-430
15. Stempel D.A., O'Donnell J.C., and Meyer J.W. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 109 (2002) 433-439
16. Ceylan E., Gencer M., and Aksoy S. Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control. Respiration 71 (2004) 594-601
17. Storms W., Chervinsky P., Ghannam A.F., Bird S., Hustad C.M., and Edelman J.M. Challenge-Rescue Study Group. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 98 (2004) 1051-1062
18. Ram F., Cates C., and Ducharme F. Long-acting beta2-agonists versus anti-leukotrienes as addon therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 25 (2005) CD003137
19. Fuglsang G., Vikre-Jorgensen J., Agertoft L., and Pedersen S. Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. Pediatr Pulmonol 25 (1998) 314-321
20. Bratton D.L., Lanz M.J., Miyazawa N., White C.W., and Silkoff P.E. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 28 (1999) 402-407
21. Ghiro L., Zanconato S., Rampon O., Piovan V., Pasquale M.F., and Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 20 (2002) 630-634
22. Buchvald F., and Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol 91 (2003) 309-313
23. Green R.H., Brightling C.E., McKenna S., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002) 1715-1721
24. Straub D.A., Minocchieri S., Moeller A., Hamacher J., and Wildhaber J.H. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 127 (2005) 509-514